Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

B-cell depletion is moving earlier in the myasthenia gravis (MG) treatment sequence, but its slower onset means patients may need a faster-acting bridge therapy in the meantime. Experts highlight FcRn inhibitors as a practical bridging option, especially when steroids aren't ideal. Antibody subtype — particularly MuSK-positive MG — plays a key role in deciding when to prioritize B-cell–directed approaches.
B-cell–depleting therapies are gaining ground in the treatment of myasthenia gravis (MG), with clinicians increasingly considering them earlier in the treatment sequence. Experts highlight CD20-directed rituximab and CD19-directed inebilizumab as key options, noting that the best timing for B-cell depletion depends on a patient's antibody subtype, prior therapy, and available clinical evidence. MuSK-positive MG stands out as a case where B-cell–directed therapy may be prioritized due to the underlying biology of antibody production.
One major practical challenge: B-cell therapies are slow to kick in, with clinical benefits sometimes taking several months to fully emerge. That lag creates a real need for a bridging strategy — and FcRn inhibitors are emerging as a strong candidate, offering faster disease control while the B-cell therapy takes hold. Once B-cell depletion achieves adequate control, FcRn therapy can be tapered or withdrawn.
Key Takeaways:
Why it matters: As the MG treatment landscape expands, sequencing therapies strategically — rather than using a one-size-fits-all approach — could meaningfully improve outcomes for patients with this complex autoimmune disease.